EClinCloud Surpasses 1,100 Clinical Trials as Its Unified AI-Driven Platform Expands Across 10+ Countries
核心洞察
EClinCloud (搜索)'s unified, AI-driven clinical research platform now supports more than 1,100 clinical trials for 300+ sponsor and research organizations across 10+ countries and regions.
The platform integrates EDC, RTSM, eCOA, IRC, CTMS, eTMF, resource management and eLearning on a single data model, audit trail and workflow engine.
Embedded AI agents auto-configure study builds (cutting effort by roughly 60%) and capture source data via medical OCR at 95%+ accuracy across 1,000+ form types.
EClinCloud (搜索) (Ningbo) Technology Co., Ltd., developer of a unified, AI-driven clinical research platform, announced that its technology now supports more than 1,100 clinical trials for 300+ sponsor and research organizations in 10+ countries and regions, including the United States, Canada, the United Kingdom, Spain, Poland, Pakistan, Georgia, Australia, New Zealand and China. The company describes the milestone as reflecting its market position: connected clinical evidence on one platform, built in China, engineered to global standards, and ready for studies worldwide.
The platform replaces the patchwork of point systems that many trials still run on, combining electronic data capture (EDC), randomization and trial supply management (RTSM), electronic clinical outcome assessments (eCOA), independent review committee (IRC) services, clinical trial management (CTMS), electronic trial master file (eTMF), resource management and eLearning on one data model, one audit trail and one workflow engine. Data entered once is visible in real time to every authorized role, and documents file continuously to the eTMF for inspection readiness.
An AI-Native Foundation
At EClinCloud (搜索), artificial intelligence is not an add-on but the company's founding premise. Built as an AI-native clinical trial company, EClinCloud has explored the fusion of AI and clinical research since its inception, pairing deep AI engineering capability with equally deep clinical research expertise as AI continues to gain momentum across the global clinical research market.
Role-based agents parse protocols to auto-configure study builds, which the company reports cuts build effort by roughly 60%; capture source data by medical OCR at 95%+ accuracy across 1,000+ form types; and model trial risk in real time for project managers. In 2026, EClinCloud (搜索) launched its embedded AI agent and next-generation IRC platform.
Compliance and Certification
EClinCloud (搜索)'s AI management system is certified to ISO/IEC 42001:2023, alongside ISO 27001/27701 security certifications, with workflows aligned with 21 CFR Part 11, EU Annex 11, ICH GCP, GDPR and HIPAA.
"Clinical research is evolving rapidly across global markets," said Michael Qin, PhD, Founder and Chief Executive Officer of EClinCloud (搜索). "We built this platform inside one of the world's highest-volume trial environments and engineered it to international standards from day one. When data, operations and endpoint assessment share one backbone, teams see issues earlier and decide with confidence — in any market."
Customer Base and Global Footprint
The company's customer base — 54% pharmaceutical companies, 23% biotechs and 17% contract research organizations, with device manufacturers and research institutions making up the remainder — positions EClinCloud (搜索) as an alternative to multi-vendor eClinical stacks for sponsors running multi-regional trials.
Headquartered in Ningbo with offices in Beijing, Shanghai, Chengdu, Shenzhen and New York, and teams operating across China, the U.S., Japan and Singapore, EClinCloud (搜索) pairs local operating knowledge with region-ready workflows and 24/7 multilingual support.